Ultragenyx Pharmaceutical Inc. (RARE) Cash Flow Statement

Because operating cash outflows roughly equal or slightly exceed net losses in most periods, the earnings quality concern here is less about aggressive accounting and more about the structural absence of positive cash generation. The 2026Q3 OCF/NI ratio of 0.36 reflects a working capital inflow of $46.0M that masked a larger underlying loss, which investors should treat as a timing benefit rather than a durable improvement. Stock-based compensation of $30M to $41.6M per quarter is a meaningful non-cash add-back, yet even after adding it back, operating cash flow remains negative, suggesting the cash burn is real and not simply an artifact of SBC.

The FCF margin pattern shows no sustained path toward breakeven, with the least negative quarter at -26.0% in 2026Q3 still representing a substantial cash drain relative to revenue. Capital expenditure is negligible, at roughly 0.4% to 1.5% of revenue, so the FCF deficit is almost entirely an operating phenomenon driven by development spending. This suggests that funding requirements are dictated by R&D intensity rather than physical investment, and the trajectory warrants monitoring for any sustained narrowing of the operating burn.

Given CapEx figures under $2.5M per quarter, the company's cash needs are not driven by maintenance or growth in physical plant, which is consistent with an outsourced manufacturing and development model. D&A of roughly $8M to $9M per quarter exceeds CapEx by a wide margin, which may indicate amortization of acquired intangibles rather than replacement of productive assets. Investors should monitor whether the company's reliance on contract manufacturers for gene therapy production creates future capital requirements that are not visible in current CapEx levels.

The absence of dividends and repurchases is consistent with a company in an operating deficit, where any capital raised would be consumed by R&D and commercial spending. Because free cash flow is consistently negative, the company has no internally generated capital for deployment, meaning past and future pipeline funding depends on external financing or partnership proceeds. The reported cash balance of $434M against sustained quarterly burn suggests the runway is finite and warrants close attention to upcoming financing decisions.

Summing reported quarterly figures, operating cash flow has been materially more negative than net income in several periods, such as 2026Q1 where OCF of -$197.0M exceeded the -$185.0M net loss, indicating that working capital and other operating items have added to cash consumption. This divergence suggests the reported loss figures understate the pace of cash depletion in certain quarters. Investors should treat the cash balance as the more relevant constraint on the business than accounting profitability.